Cross-reactivity between vancomycin, teicoplanin, and telavancin in patients with HLA-A?32:01–positive vancomycin-induced DRESS sharing an HLA class II haplotype - 09/01/21
E.J.P. receives funding from the National Institutes of Health (grants 1P50GM115305-01, R21AI139021, R34AI136815, and 1 R01 HG010863-01) and the National Health and Medical Research Council of Australia). J.A.T. is supported by a National Health and Medical Research Council postgraduate scholarship (GNT 1139902) and postgraduate scholarship from the National Centre for Infections in Cancer. K.C.K. is supported by the National Institutes of Health (grants F30AI131780 and T32GM7347). |
|
Disclosure of potential conflict of interest: E. J. Phillips and K. C. Konvinse hold a provisional patent for the detecton of HLA-A∗32:01 in connection with determining DRESS. The rest of the authors declare that they have no relevant conflicts of interest. |
Vol 147 - N° 1
P. 403-405 - janvier 2021 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?